From Patient Care to Discovery in Rare Blood Cancer: Three Stories from the PETAL Consortium
This piece was originally written by Audrey Zhang
People with rare blood cancer disorders often face a long and challenging journey when it comes to finding the answers to questions about their condition and prognosis.
For patients with peripheral T-cell lymphoma (PTCL), this journey can be particularly complex, for PTCL is not one disease, but a group of rare blood cancers with multiple subtypes, each requiring specialized expertise.
Salvia Jain, MD
At Mass General Brigham, hematologist-oncologist Salvia Jain, MD, helps to coordinate care for patients with PTCL while simultaneously leading research into this rare blood cancer and other related disorders through the collaborative PETAL Consortium, an international effort of over 100 investigators from 20 research sites.
This Blood Cancer Awareness Month, we’re sharing three stories of strength and resilience, and the people and research working to change what a PTCL diagnosis can mean.
Henry: Turning a Difficult Diagnosis into a Commitment to Research
When Henry was a student and baseball player at Middlebury College, PTCL changed the course of his life. After developing chest tightness, fevers and body aches, he was diagnosed with the rare blood cancer and began treatment at Mass General Brigham.
He underwent chemotherapy and a stem cell transplant, but later relapsed and required additional treatment—including a second transplant using stem cells from his brother.
Through it all, Henry remained connected to his family, friends, school and baseball. His experience also inspired his family to turn their support into action. Through Henry Strong, they raised more than $50,000 to support lymphoma research.
That funding helped the PETAL Consortium purchase a microbioreactor, a device that researchers use to grow lymphoma cells and study the disease in the laboratory.
Karen: When the Right Diagnosis Changes Everything
In April 2023, Karen began feeling sick and was severely swollen. She had fluid retention, eventually gaining nearly 60 pounds of fluid, and had difficulty breathing. After repeated ER visits and treatment for strep A and scarlet fever, doctors could still not find an explanation for her symptoms.
Her blood pressure dropped, she went into cardiac arrest and finally, a biopsy revealed that she had PTCL. She was intubated and transferred to Mass General Brigham.
Karen's experience underscores one of the challenges of rare cancers: Getting the right diagnosis can take time. At MGB, Karen's care included intensive treatment, chemotherapy and a stem cell transplant. Her recovery was difficult and included an ICU stay, but she is now in remission.
Looking back, Karen emphasizes the importance of having an advocate to look out for you—especially when as a patient, you are too sick to speak for yourself. Her husband and family continued pushing for answers when she could not. See Karen's full interview here.
Christine: The Difference Specialized Care Can Make
Christine initially experienced fatigue that progressed to night sweats, bloating, abdominal pain and back pain. After several appointments at local hospitals without a clear explanation, her husband brought her to Mass General Brigham.
At MGB, Christine was quickly connected with the specialized team at PETAL and received a diagnosis and treatment plan within days. For her, getting to the right experts changed the course of her care, and gave her confidence in the path ahead.
Today, Christine is thriving in remission.
Her story illustrates why expertise matters in rare cancers. When a disease is uncommon and its symptoms can overlap with many other conditions, specialized knowledge can help patients move more quickly from uncertainty to answers and treatment. See Christine's full interview here.
Learn more about the PETAL Consortium
In 2023, Salvia Jain, MD, a hematologist-oncologist at Massachusetts General Hospital, recognized the lack of systematic, multimodal longitudinal data for patients with peripheral T-cell lymphoma (PTCL). In response, she founded PETAL Consortium—a first-of-its-kind global network dedicated to advancing care for this rare and aggressive blood cancer by serving as a central hub of information.